Saturday, 26. September 2026 · Next update: 22:00 DE EN Log in
Cassandra.news
Tomorrow's news. Today.
💻 Technology · Next Month

Meta Platforms (NASDAQ: META) reports total revenue above $62.0 billion in the Q3 FY2026 earnings report (approx. October 29, 2026, confirmed by Meta Investor Relations or Bloomberg by October 30, 2026)

Pending ✦ AI-generated prediction Published on 26. September 2026 · Predicted for 29. October 2026 · Based on: Historical Cycle
Probability
50%

Meta reported Q2 2026 total revenue of $60.80bn (+28% YoY), driven by Family of Apps ad revenue (+27% to $59.4bn), Instagram reaching 2bn daily actives, and Meta AI interactions up 60% (Muse Spark integration). Q3 historically follows a slight positive sequential pattern: in 2024 revenue rose ~+3.8% from Q2 ($39.1bn) to Q3 ($40.6bn). Applying the same ~+3.8% sequential to Q2 2026: 60.80 × 1.038 = ~$63.1bn. The $62.0bn threshold sits just below that. YoY benchmark: Q3 2025 was ~$48.7bn; +27% = $61.8bn, +28% = $62.3bn. Polymarket lists no dedicated Meta Q3 revenue market. Probability ~50% — the threshold sits near the median estimate. Risks: regulation, AI opex escalation, ad market softening. No buy/sell recommendation.

Data basis for this prediction
  • Meta Platforms Q2 2026 Earnings: $60,80 Mrd. Gesamtumsatz, +28 % YoY (Yahoo Finance / SEC 8-K, 30.07.2026)
  • Meta Q2 2026 Earnings Call Highlights: Instagram 2 Mrd. Daily Actives, Meta AI +60 % (quartr.com, 30.07.2026)
  • Meta Q3 2024 Earnings: $40,6 Mrd. (+3,8 % sequenziell vs. Q2 2024's $39,1 Mrd.) — Saisonalitäts-Referenz
  • Polymarket Finance Markets (26.09.2026): kein spezifisches META-Q3-Revenue-Market gelistet

Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.

Verdict: Pending
This prediction is still open. It will be evaluated automatically against real-world sources after its due date.
Related Predictions
💻 Technology ✦ AI

Nobel Prize in Chemistry 2026 awarded to David R. Liu (Harvard University) for base editing and prime editing

David R. Liu (Harvard University) is the frontrunner according to the 2026 Clarivate Citation Laureates – for developing base editing and prime editing, precise DNA-repair tools that build on the CRISPR platform and hold broad therapeutic promise for hereditary diseases. Liu received the 2025 Breakthrough Prize for this work. Other strong candidates: Harry Gray & Jay Winkler (Caltech, electron transfer in proteins) and Allara/Nuzzo/Sagiv (self-assembled monolayers). No Polymarket/Kalshi market found for the Chemistry prize; the 27% probability is based on Clarivate's track record (~89 subsequent Nobel laureates from ~500 nominees since 2002), ACS C&EN expert polls, and breadth of the candidate field. Announcement: October 7, 2026, 11:45 CEST, Royal Swedish Academy of Sciences.

27%
Next Month · Predicted for 7. Oct 2026
💻 Technology ✦ AI

2026 Nobel Prize in Physics awarded to Pablo Jarrillo-Herrero (MIT), H. Allan MacDonald (UT Austin), and Rafi Bistritzer for discovering superconductivity in magic-angle twisted bilayer graphene (announcement October 6, 2026)

Bistritzer & MacDonald predicted in 2011 the twist angle at which bilayer graphene would exhibit exotic quantum properties ('magic angle'). Jarrillo-Herrero's MIT group confirmed this experimentally in 2018, discovering unexpected superconductivity at ~1.1° — launching the field of Moiré quantum materials. Kalshi hosts a Nobel Physics 2026 market; specific odds not retrievable. Among roughly 6–8 serious candidate groups (including Jun Ye & Hidetoshi Katori for optical lattice clocks), Twisted Graphene ranks top 3. Nobel Physics remains structurally hard to predict.

20%
Next Week · Predicted for 6. Oct 2026
💻 Technology ✦ AI

Nobel Prize in Physiology or Medicine 2026 awarded for GLP-1 incretin research (Jens Juul Holst, Svetlana Mojsov and/or Daniel J. Drucker; announcement October 5, 2026)

Jens Juul Holst (University of Copenhagen), Svetlana Mojsov (Rockefeller University) and Daniel J. Drucker (Lunenfeld-Tanenbaum Research Institute, Toronto) were named Clarivate Citation Laureates 2026 on September 17, 2026 for GLP-1 foundational research — the basis for semaglutide (Ozempic/Wegovy) and tirzepatide. Lotte Bjerre Knudsen (Novo Nordisk) is cited as pharmacological complement. GLP-1 is rated the leading candidate field for the 2026 Medicine Nobel by medium.com and oneseventynine.ai. With ~15 competing candidate constellations, single-field probability is approximately 20–25%; no dedicated Polymarket market available.

23%
Next Week · Predicted for 5. Oct 2026